Extramammary Paget's disease

Last updated
Extramammary Paget's disease
Extramammary Paget disease - high mag.jpg
Micrograph of extramammary Paget's disease, H&E stain
Specialty Dermatology, Oncology
Symptoms Rash, Itchiness, Eczematous lesions, Pain
CausesUnknown
Diagnostic method Excisional biopsy, histological pattern
Named after James Paget

Extramammary Paget's disease (EMPD) is a rare and slow-growing malignancy which occurs within the epithelium [1] and accounts for 6.5% of all Paget's disease. [2] The clinical presentation of this disease is similar to the characteristics of mammary Paget's disease (MPD). [3] However, unlike MPD, which occurs in large lactiferous ducts and then extends into the epidermis, [3] EMPD originates in glandular regions rich in apocrine secretions outside the mammary glands. [4] EMPD incidence is increasing by 3.2% every year, affecting hormonally-targeted tissues such as the vulva and scrotum. [5] In women, 81.3% of EMPD cases are related to the vulva, while for men, 43.2% of the manifestations present at the scrotum. [5]

Contents

The disease can be classified as being either primary or secondary depending on the presence or absence of associated malignancies. [6] EMPD presents with typical symptoms such as scaly, erythematous, eczematous lesions accompanied by itchiness. [6] In addition to this, 10% of patients are often asymptomatic. [7] As a consequence, EMPD has high rates of misdiagnoses and delayed diagnoses. [8] There are a variety of treatment options available, but most are unsuccessful. If caught early and treated, prognosis is generally good.

Presentation

Patients with EMPD present with typical symptoms, similar to MPD, [3] such as severe itchiness (also called pruritus), rash, plaque formation, burning sensation, pain and tenderness. [7] These symptoms are often confused for dermatitis or eczema. [8] 10% of patients are asymptomatic resulting in delayed diagnosis. [7] In rare cases bleeding can also be seen. [9]

Symptoms of extramammary Paget's disease [7]
Skin
  • transient rash
  • itchiness
  • erythematous
  • well-demarcated, non-resolving, eczematous plaque
  • hyperpigmented patches
  • scaly
  • lump
  • thickened skin, appearing leathery
Discharge
  • blood
  • ulceration
Sensation
  • burning sensation
  • tenderness
  • pain

Disease of the vulva

Vulvar Paget's disease affect women and presents as erythematous (red), eczematous lesions. [10] It is itchy and sometimes pain can be associated with the affected area. [10] The lesion is clearly separated from normal skin in most cases, and sometimes scattered areas of white scale can be present, giving a "strawberries and cream" appearance. [11]

Involvement may be extensive including the perianal region, genitocrural, and inguinal folds. Clinical examination should determine the presence of periurethral and perianal lesions. [12] In these cases an involvement of the skin by a noncutaneous internal neoplasm may occur. [12]

Pathophysiology

H&E stained micrograph of Extramammary Paget's disease, showing Paget cells infiltrating the epidermis Extramammary Paget disease - w cond - very high mag.jpg
H&E stained micrograph of Extramammary Paget's disease, showing Paget cells infiltrating the epidermis

EMPD occurs due to an invasion of the epidermis by Paget cells. [2] The cause of the disease is still under debate with recent research indicating that the disease may be associated with Toker cells. [13]

Disease of the vulva

Originates from local organs such as the Bartholin gland, the urethra, or the rectum. [14] Predilection towards postmenopausal women. [14]

Metastatic disease

Metastasis of Paget cells from the epidermis to distant regions is a multistep process that involves:

  1. Invasion of local lymph nodes and venous system [4]
  2. Movement out from lymph nodes and venous system [4]
  3. Proliferation at new site [4]

Protein molecules HER2 and mTOR expressed in Paget cells are responsible for providing characteristics of proliferation and survival. [4]

Diagnosis

Due to the rarity of EMPD and lack of clinical knowledge, the disease is not very commonly diagnosed. [8] Patients are often misdiagnosed with eczema or dermatitis [8] and a delay of 2 years is expected from the onset of symptoms before a definitive diagnosis has been reached. [8]

It is important to include that the lesion is associated with another cancer. A biopsy will establish the diagnosis. Punch biopsies are not effective in differentially diagnosing for EMPD and as a result, excisional biopsies of the affected area are taken [XX]. A positive test result for EMPD shows increased numbers of large polygonal cells with a pale bluish cytoplasm, large nucleus and nucleolus, infiltrating the epidermal layer. [7] These neoplastic cells can be found singly scattered or can appear in groups called nests. [7]

Paget cells contain mucin and cytokeratins which can be used in the diagnosis of EMPD [8] MUC5A2 is found in EMPD of the vulvar and male genitalia regions whereas MUC2 is expressed in perianal EMPD. Loss of MUC5A2 can indicate an invasive spread. [15] Immunohistochemistry (IHC) can be used to determine whether EMPD is either primary or secondary. [15] Primary EMPD tests positive for CK7 but negative for CK20, whereas secondary is positive for both. [15] Lack of positivity for hormone receptors and HER2 protein is overexpressed meaning that the cells are dividing rapidly and can be indicate an aggressive and more recurrent disease.[ citation needed ]

Classification

Primary EMPD is of cutaneous origins and is found within the epidermis or the underlying apocrine glands. [1] Although it is limited to the epithelium, it has potential to spread and progress into an invasive tumour, metastasising to the local lymph nodes and distant organs. [6] This form of EMPD is not associated with an adenocarcinoma. [1]

The secondary form results due to an underlying adenocarcinoma spreading to the epidermis. [15] Similar to the primary form, if secondary EMPD invades the dermis, the neoplastic cells can metastasise to the lymph nodes and in some cases, the dermis. [4]

According to the Wilkinson and Brown subclassification system, there are three subtypes for each classification. [16]

Sub-classifications of primary and secondary extramammary disease [16]
Primary (cutaneous)Secondary (non-cutaneous)
Intraepithelial cutaneous Paget disease of the usual typeAnorectal
Intraepithelial cutaneous Paget disease with invasionUrothelial
Intraepithelial cutaneous Paget disease as a manifestation of underlying

adenocarcinoma of skin appendage

Other

Treatment

Many chemotherapy treatments have been used, however the results are not desirable as prognosis remains to be poor. [16] Surgery remains to be the preferred treatment of choice. Wide local excision with a 3 cm margin and intra-operative frozen sections are suggested, due to high risk of local extension despite normal appearing tissue. In cases where Paget cells have invaded the dermis and metastasized, complete removal is often unsuccessful. Recurrence is a common result. [15] Lymphadenoectomy is often performed for infiltrative cases. [16] In lieu of surgery, radiotherapy is also an option and is especially preferred for elderly patients or for inoperable cases where the tumour size is too large. [6] This form of treatment is also considered as possible adjuvant therapy following excision to combat the high recurrence rate. [2] However, there are side effects of radiotherapy, including but not limited to: vulvitis, post-radiation atrophy of mucus membranes, vaginal stenosis and sexual dysfunction. [2]

Laser therapy and photodynamic therapies were also used in the past, but it was discovered the carbon dioxide laser did not penetrate deep enough and both treatment modalities resulted in high recurrence rates. [2]

Topical chemotherapy treatments are effective, with imiquimod showing promising results. [2] However, overall survival begins to decline 10 months following treatment with chemotherapy. [4] Patients with metastatic EMPD only survive for a median of 1.5 years, and have a 7% 5-year survival rate. [4]

Prognosis

Prognosis is generally good, but factors such as depth of invasion and duration of disease need to be considered. [16] In primary EMPD, if invasion of the underlying tissue is non-existent or even minimal, treatment options are more likely to be effective, however, if there are signs that the disease has metastasised, the prognosis is usually poor. [3]

Epidemiology

EMPD is most prevalent in Caucasian women and Asian men over the age of 60. [9] The invasive form occurs in 5–25% of all EMPD patients and 17–30% of the cases involve an underlying adenocarcinoma. [16] 10-20% of EMPD is of the secondary form. [16] Approximately 10% of patients develop invasive adenocarcinoma that may progress to metastatic disease. [17]

The disease affects regions that are rich in apocrine secretions. [4] 65% EMPD occurs at the vulva, [15] followed by 15% at perianal areas and 14% at the male genitalia. [2] In terms of the vulva, the labia majora is the site that is most often involved, followed by labia minora, clitoris and perineum. [16] EMPD originating at the vulva can spread to the upper vaginal mucosa and cervix. [16] Other areas where EMPD can be found, although very rarely, include: the axillae, eyelids, external auditory canal, umbilical region, trunk and extremities. [2]

History

The first case of Paget's disease was described by James Paget in 1874. [3] Radcliffe Crocker, in 1889, then described EMPD following an observation of a patient with urinary carcinoma affecting the penis and scrotum, [18] showing symptoms that were almost identical to MPD as described by Paget. [6] Later in 1893, Darier and Coulillaud described the perianal location of EMPD. [6]

Related Research Articles

Penile cancer, or penile carcinoma, is a cancer that develops in the skin or tissues of the penis. Symptoms may include abnormal growth, an ulcer or sore on the skin of the penis, and bleeding or foul smelling discharge.

<span class="mw-page-title-main">Paget's disease of the breast</span> Medical condition

Paget's disease of the breast is a type of cancer that outwardly may have the appearance of eczema, with skin changes involving the nipple of the breast. The condition is an uncommon disease accounting for 1 to 4.3% of all breast cancers and was first described by Sir James Paget in 1874.

<span class="mw-page-title-main">Pseudomyxoma peritonei</span> Medical condition

Pseudomyxoma peritonei (PMP) is a clinical condition caused by cancerous cells that produce abundant mucin or gelatinous ascites. The tumors cause fibrosis of tissues and impede digestion or organ function, and if left untreated, the tumors and mucin they produce will fill the abdominal cavity. This will result in compression of organs and will destroy the function of the colon, small intestine, stomach, or other organs. Prognosis with treatment in many cases is optimistic, but the disease is lethal if untreated, with death occurring via cachexia, bowel obstruction, or other types of complications.

Vulvitis is inflammation of the vulva, the external female mammalian genitalia that include the labia majora, labia minora, clitoris, and introitus. It may co-occur as vulvovaginitis with vaginitis, inflammation of the vagina, and may have infectious or non-infectious causes. The warm and moist conditions of the vulva make it easily affected. Vulvitis is prone to occur in any female especially those who have certain sensitivities, infections, allergies, or diseases that make them likely to have vulvitis. Postmenopausal women and prepubescent girls are more prone to be affected by it, as compared to women in their menstruation period. It is so because they have low estrogen levels which makes their vulvar tissue thin and dry. Women having diabetes are also prone to be affected by vulvitis due to the high sugar content in their cells, increasing their vulnerability. Vulvitis is not a disease, it is just an inflammation caused by an infection, allergy or injury. Vulvitis may also be symptom of any sexually transmitted disease or a fungal infection.

<span class="mw-page-title-main">Angiokeratoma</span> Medical condition

Angiokeratoma is a benign cutaneous lesion of capillaries, resulting in small marks of red to blue color and characterized by hyperkeratosis. Angiokeratoma corporis diffusum refers to Fabry's disease, but this is usually considered a distinct condition.

<span class="mw-page-title-main">Vulvar cancer</span> Cancer involving the vulva

Vulvar cancer is a cancer of the vulva, the outer portion of the female genitals. It most commonly affects the labia majora. Less often, the labia minora, clitoris, or vaginal glands are affected. Symptoms include a lump, itchiness, changes in the skin, or bleeding from the vulva.

<span class="mw-page-title-main">Vulvar intraepithelial neoplasia</span> Medical condition

Vulvar intraepithelial neoplasia (VIN) refers to particular changes that can occur in the skin that covers the vulva. VIN is an intraepithelial neoplasia, and can disappear without treatment. VINs are benign but if the changes become more severe, there is a chance of cancer developing after many years, and so it is referred to as a precancerous condition.

Gynecologic oncology is a specialized field of medicine that focuses on cancers of the female reproductive system, including ovarian cancer, uterine cancer, vaginal cancer, cervical cancer, and vulvar cancer. As specialists, they have extensive training in the diagnosis and treatment of these cancers.

<span class="mw-page-title-main">Papillary hidradenoma</span> Medical condition

A papillary hidradenoma, also termed hidradenoma papilliferum or mammary-like gland adenoma of the vulva, is a rare, but nonetheless most common benign tumor that occurs in and between anal and genital regions of females. These hidradenomas are sharply circumscribed, nodular tumors that usually develop in women's anogenital area but uncommonly occur in other sites in women and men. Papillary hidradenomas that develop outside of the anogenital region are termed ecctopic papillary hidradenomas or ectopic hidradenoma papilliferums.

Verruciform xanthoma is an uncommon benign lesion that has a verruciform (wart-like) appearance, but it may appear polypoid, papillomatous, or sessile. The verruciform was first described by Shafer in 1971 on the oral mucosa. Usually found on the oral mucosa of middle-aged persons, verruciform xanthomas have also been reported on the scrotum and penis of middle-aged to elderly Japanese males. While the most common site is the oral mucosa, lesions that occur elsewhere usually arise on the perineum or on the skin with some predisposing factor, such as lymphedema or an epidermal nevus.

<span class="mw-page-title-main">Langerhans cell sarcoma</span> Medical condition

Langerhans cell sarcoma (LCS) is a rare form of malignant histiocytosis. It should not be confused with Langerhans cell histiocytosis, which is cytologically benign. It can present most commonly in the skin and lymphatic tissue, but may also present in the lung, liver, and bone marrow. Treatment is most commonly with surgery or chemotherapy.

<span class="mw-page-title-main">Poroma</span>

Poromas are rare, benign, cutaneous adnexal tumors. Cutaneous adnexal tumors are a group of skin tumors consisting of tissues that have differentiated towards one or more of the four primary adnexal structures found in normal skin: hair follicles, sebaceous sweat glands, apocrine sweat glands, and eccrine sweat glands. Poromas are eccrine or apocrine sweat gland tumors derived from the cells in the terminal portion of these glands' ducts. This part of the sweat gland duct is termed the acrosyringium and had led to grouping poromas in the acrospiroma class of skin tumors. Here, poromas are regarded as distinct sweat gland tumors that differ from other sweat gland tumors by their characteristic clinical presentations, microscopic histopathology, and the genetic mutations that their neoplastic cells have recently been found to carry.

Porocarcinoma (PCA) is a rare form of skin cancer that develops in eccrine sweat glands, i.e. the body's widely distributed major type of sweat glands, as opposed to the apocrine sweat glands which are located primarily in the armpits and perineal area. This cancer typically develops in individuals as a single cutaneous tumor in the intraepidermal spiral part of these sweat glands' ducts at or near to where they open on the skin's surface. PCA tumors are classified as one form of the cutaneous adnexal tumors; in a study of 2,205 cases, PCA was the most common (11.8%) form of these tumors.

<span class="mw-page-title-main">Spiradenoma</span> Medical condition

Spiradenomas (SA) are rare, benign cutaneous adnexal tumors that may progress to become their malignant counterparts, i.e. spiradenocarcinomas (SAC). Cutaneous adnexal tumors are a group of skin tumors consisting of tissues that have differentiated towards one of the four primary adnexal structures found in normal skin: hair follicles, sebaceous sweat glands, apocrine sweat glands, and eccrine sweat glands. SA and SAC tumors were regarded as eccrine gland tumors and termed eccrine spiradenomas and eccrine spiradenocarcinomas, respectively. However, more recent studies have found them to be hair follicle tumors and commonly term them spiradenomas and spiradenocarcinomas, respectively. Further confusing the situation, SA-like and SAC-like tumors are also 1) manifestations of the inherited disorder, CYLD cutaneous syndrome (CCS), and 2) have repeatedly been confused with an entirely different tumor, adenoid cystic carcinomas of the salivary gland. Here, SA and SAC are strictly defined as sporadic hair follicle tumors that do not include the hereditary CCS spiradenomas and heridtary spiradenocarcinoms of CCS or the adenoid cystic carcinomas.

<span class="mw-page-title-main">Mammary-type myofibroblastoma</span> Medical condition

Mammary-type myofibroblastoma (MFB), also named mammary and extramammary myofibroblastoma, was first termed myofibrolastoma of the breast, or, more simply, either mammary myofibroblastoma (MMFB) or just myofibroblastoma. The change in this terminology occurred because the initial 1987 study and many subsequent studies found this tumor only in breast tissue. However, a 2001 study followed by numerous reports found tumors with the microscopic histopathology and other key features of mammary MFB in a wide range of organs and tissues. Further complicating the issue, early studies on MFB classified it as one of various types of spindle cell tumors that, except for MFB, were ill-defined. These other tumors, which have often been named interchangeably in different reports, are: myelofibroblastoma, benign spindle cell tumor, fibroma, spindle cell lipoma, myogenic stromal tumor, and solitary stromal tumor. Finally, studies suggest that spindle cell lipoma and cellular angiofibroma are variants of MFB. Here, the latter two tumors are tentatively classified as MFB variants but otherwise MFB is described as it is more strictly defined in most recent publications. The World Health Organization in 2020 classified mammary type myofibroblastoma tumors and myofibroblastoma tumors as separate tumor forms within the category of fibroblastic and myofibroblastic tumors.

<span class="mw-page-title-main">Bartholin gland carcinoma</span> Medical condition

Bartholin gland carcinoma is a type of cancer of the vulva arising in the Bartholin gland. It typically presents with a painless mass at one side of the vaginal opening in a female of middle-age and older, and can appear similar to a Bartholin cyst. The mass may be big or small, may be deep under skin or appear nearer the surface with overlying ulceration. Average age at presentation is 53-years.

Vaginal melanoma is a rare malignancy that originates from melanocytes in the vaginal epithelium. It is also known as a melanocytic tumor or as a malignant melanoma. It is aggressive and infrequently cured. The median overall survival is 16 months. Vaginal melanoma accounts 5.5% of all vaginal cancers and only 1% of all melanomas diagnosed in women. Vaginal melanomas are frequently diagnosed in advanced stages of the disease. The prognosis is poor and the most important risk factor is the presence of lymph node metastases.

Crohn's disease (CD) of the vulva is a rare extra intestinal condition, with granulomatous cutaneous lesions affecting the female genitalia. Lesions connected to the affected gut via a healthy tissue are referred to as metastatic lesions.

Vulvar tumors are those neoplasms of the vulva. Vulvar and vaginal neoplasms make up a small percentage (3%) of female genital cancers. They can be benign or malignant. Vulvar neoplasms are divided into cystic or solid lesions and other mixed types. Vulvar cancers are those malignant neoplasms that originate from vulvar epithelium, while vulvar sarcomas develop from non-epithelial cells such as bone, cartilage, fat, muscle, blood vessels, or other connective or supportive tissue. Epithelial and mesenchymal tissue are the origin of vulvar tumors.

References

  1. 1 2 3 Isrow D, Oregel KZ, Cortes J, Gomez H, Milikowski C, Feun L, Silva O (2014-07-06). "Advanced Extramammary Paget's Disease of the Groin, Penis, and Scrotum". Clinical Medicine Insights: Oncology. 8: 87–90. doi:10.4137/CMO.S13107. PMC   4116380 . PMID   25089091.
  2. 1 2 3 4 5 6 7 8 Wagner G, Sachse MM (June 2011). "Extramammary Paget disease - clinical appearance, pathogenesis, management". Journal der Deutschen Dermatologischen Gesellschaft. 9 (6): 448–54. doi: 10.1111/j.1610-0387.2010.07581.x . PMID   21205169.
  3. 1 2 3 4 5 Lloyd J, Flanagan AM (October 2000). "Mammary and extramammary Paget's disease". Journal of Clinical Pathology. 53 (10): 742–9. doi:10.1136/jcp.53.10.742. PMC   1731095 . PMID   11064666.
  4. 1 2 3 4 5 6 7 8 9 Fukuda K, Funakoshi T (2018-02-16). "Metastatic Extramammary Paget's Disease: Pathogenesis and Novel Therapeutic Approach". Frontiers in Oncology. 8: 38. doi: 10.3389/fonc.2018.00038 . PMC   5820294 . PMID   29503810.
  5. 1 2 Zhou S, Zhong W, Mai R, Zhang G (2017). "Mammary and Extramammary Paget's Disease Presented Different Expression Pattern of Steroid Hormone Receptors". BioMed Research International. 2017: 3768247. doi: 10.1155/2017/3768247 . PMC   5610822 . PMID   29082243.
  6. 1 2 3 4 5 6 Lopes Filho LL, Lopes IM, Lopes LR, Enokihara MM, Michalany AO, Matsunaga N (April 2015). "Mammary and extramammary Paget's disease". Anais Brasileiros de Dermatologia. 90 (2): 225–31. doi:10.1590/abd1806-4841.20153189. PMC   4371672 . PMID   25830993.
  7. 1 2 3 4 5 6 Konda S, Chen W, Minus HR (March 2015). "What is your diagnosis? Extramammary Paget disease". Cutis. 95 (3): 132, 135–6, 142. PMID   25844784.
  8. 1 2 3 4 5 Hsu L, Shen Y, Chen C, Sung M, Chiang P (March 2013). "Extramammary Paget's disease with invasive adenocarcinoma of the penoscrotum: Case report and systematic review". Urological Science. 24 (1): 30–33. doi: 10.1016/j.urols.2013.01.003 . ISSN   1879-5226.
  9. 1 2 Kang Z, Zhang Q, Zhang Q, Li X, Hu T, Xu X, Wu Z, Zhang X, Wang H, Xu J, Xu F, Guan M (2015). "Clinical and pathological characteristics of extramammary Paget's disease: report of 246 Chinese male patients". International Journal of Clinical and Experimental Pathology. 8 (10): 13233–40. PMC   4680468 . PMID   26722523.
  10. 1 2 Anton C, Luiz AV, Carvalho FM, Baracat EC, Carvalho JP (June 2011). "Clinical treatment of vulvar Paget's disease: a case report". Clinics. 66 (6): 1109–11. doi:10.1590/S1807-59322011000600033. PMC   3129957 . PMID   21808885.
  11. ↑ Bolognia J, Jorizzo JL, Schaffer JV (2012). Dermatology. Bolognia, Jean., Jorizzo, Joseph L., Schaffer, Julie V. (3rd ed.). [Philadelphia]: Elsevier Saunders. ISBN   9780702051821. OCLC   802040381.
  12. 1 2 Preti M, Micheletti L, Massobrio M, Ansai S, Wilkinson EJ (April 2003). "Vulvar paget disease: one century after first reported". Journal of Lower Genital Tract Disease. 7 (2): 122–35. doi:10.1097/00128360-200304000-00009. hdl: 2318/39322 . PMID   17051057. S2CID   41852226.
  13. ↑ McDaniel, Brianna; Crane, Jonathan S. (2018), "Paget Disease, Extramammary", StatPearls, StatPearls Publishing, PMID   29630276 , retrieved 2018-06-09
  14. 1 2 Fanning J, Lambert L, Hale TM, Morris PC, Schuerch C (1999). "Paget's disease of the vulva: prevalence of associated vulvar carcinoma, invasive Paget's disease, and recurrence after surgical excision". Am J Obstet Gynecol. 180 (1 Pt 1): 24–7. doi:10.1016/s0002-9378(99)70143-2. PMID   9914572.
  15. 1 2 3 4 5 6 Lam C, Funaro D (October 2010). "Extramammary Paget's disease: Summary of current knowledge". Dermatologic Clinics. 28 (4): 807–26. doi:10.1016/j.det.2010.08.002. PMID   20883922.
  16. 1 2 3 4 5 6 7 8 9 Londero AP, Bertozzi S, Salvador S, Fruscalzo A, D'Aietti V, Grassi T, Driul L, Mariuzzi L, Marchesoni D (April 2013). "A review of extramammary paget's disease: Clinical presentation, diagnosis, management and prognosis". Journal of Medicine and Medical Sciences. 4 (4): 134–148.
  17. ↑ "International Classification of Diseases for Oncology". codes.iarc.fr. Retrieved 2018-06-09.
  18. ↑ Marques-Costa JC, Cuzzi T, Carneiro S, Parish LC, Ramos-e-Silva M (May–Jun 2012). "Paget's disease of the breast". Skinmed. 10 (3): 160–5, quiz 165. PMID   22779098.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.